The Medicines Company Announces Positive Results for Solo

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

PARSIPPANY, NJ--(Marketwired - Jul 2, 2013) - The Medicines Company ( NASDAQ : MDCO ) today announced results for its Phase 3 SOLO clinical trial program of oritavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). SOLO I and SOLO II are identical multicenter, double-blind, randomized clinical trials. The Company reported positive SOLO I results in December 2012 and report similar positive SOLO II results today.

In SOLO II, all protocol-specified primary and secondary efficacy endpoints were met. SOLO II demonstrated oritavancin to be non-inferior to vancomycin for both US and European regulators' required efficacy endpoints. All pre-specified endpoints were achieved, both for the Early Clinical Evaluation (ECE) (or 48-72 hour) required by the US Food and Drug Administration (FDA) and for the later Post Therapy Evaluation (PTE) (7-14 days after end of treatment) required by the European Medicines Agency (EMA). In SOLO II, adverse events were reported with similar frequencies on oritavancin and vancomycin.

The combined SOLO trial data demonstrated that oritavancin and vancomycin efficacy were similar for the ECE and PTE endpoints. However, in microbiologically confirmed MRSA patients, the target population for such therapies, oritavancin-treated patients achieved the FDA-proposed endpoint of greater than or equal to 20% reduction of lesion area at ECE more frequently than vancomycin-treated patients. Under the Special Protocol Assessment (SPA) agreed with the FDA, the protocols pre-specified that MRSA patients from the SOLO studies would be pooled for the evaluation of efficacy.

Commenting on the results, Clive Meanwell MD PhD, Chairman and Chief Executive Officer of The Medicines Company said: "SOLO trial data consistently show that a single dose of oritavancin given on presentation of a patient with ABSSSI to hospital can cure gram positive infections, including MRSA infections, and be at least as efficacious as multiple days of twice-daily vancomycin infusions. The safety profile also appears potentially advantageous over vancomycin. We anticipate submitting an application for oritavancin US market clearance in the fourth quarter of 2013 and a European filing in 2014."

The combined SOLO studies represent the largest patient population (1,987 patients in intent-to -treat population) evaluating an anti-infective for the treatment of ABSSSI in controlled clinical trials and have assessed one of the largest subsets of patients with documented MRSA infection (405 patients).

"The SOLO clinical trials are compelling due to the size of the program, the range of severe skin infection patients enrolled and the powerful and innovative drugs studied," said Ralph Corey MD, Professor of Medicine and Infectious Disease at Duke University and Principal Investigator of the SOLO Trials. "Given the high rate of efficacy the vancomycin comparator demonstrated in this and other similar trials, the most compelling finding in SOLO is in the pre-specified pooled findings that more oritavancin-treated MRSA patients had a greater than or equal to 20% reduction in their skin lesion up to 48 to 72 hours after treatment initiation. The benefit of an early, definitive and aggressive treatment strategy in seriously infected patients warrants additional study in skin and other severe infections, including those requiring prolonged periods of treatment."

Primary Results in SOLO II (mITT population)

Timepoint   Endpoint   Oritavancin (n = 503)   Vancomycin (n = 502)   % Difference (95% CI)
Early clinical evaluation (ECE)   FDA primary endpoint: Cessation of spread, absence of fever, no rescue antibiotics   403 (80.1%)   416 (82.9%)   -2.7 (-7.5, 2.0)
≥20% reduction of lesion area   432 (85.9%)   428 (85.3%)   0.6 (-3.7, 5.0)
Post therapy evaluation (PTE)   EMA primary endpoint: Investigator-assessed clinical cure   416 (82.7%)   404 (80.5%)   2.2 (-2.6, 7.0)

Results in patients with confirmed MRSA infections in SOLO II (Microbiological ITT population)

Timepoint   Endpoint   Oritavancin (n = 100)   Vancomycin (n = 101)
Early clinical evaluation (ECE)   FDA primary endpoint: Cessation of spread, absence of fever, no rescue antibiotics   82 (82.0%)   82 (81.2%)
≥20% reduction of lesion area   96 (96.0%)   91 (90.1%)
Post therapy evaluation (PTE)   EMA primary endpoint: Investigator-assessed clinical cure   84 (84.0%)   86 (85.1%)

Safety profiles, measured at any point up to 60 days after treatment, were similar across treatment groups in SOLO II. Overall, 50.9% of patients on oritavancin and 50.2% of patients on vancomycin were reported to experience at least one adverse event. In SOLO II, treatment emergent adverse events considered by investigators as related to study drug were reported by similar proportions of patients treated with oritavancin and vancomycin (21.7% and 25.5%, respectively).

Primary Results in SOLO I and SOLO II Combined (mITT population)

Timepoint   Endpoint   Oritavancin (n = 978)   Vancomycin (n = 981)   % Difference (95% CI)
Early clinical evaluation (ECE)   FDA primary endpoint: Cessation of spread, absence of fever, no rescue antibiotics   794 (81.2%)   794 (80.9%)   0.2 (-3.3, 3.7)
≥20% reduction of lesion area   845 (86.4%)   825 (84.1%)   2.3 (-0.9, 5.4)
Post therapy evaluation (PTE)   EMA primary endpoint: Investigator-assessed clinical cure   794 (81.2%)   787 (80.2%)   1.0 (-2.5, 4.5)

Results in patients with confirmed MRSA infections in SOLO I and SOLO II Combined (MicroITT population)

Timepoint   Endpoint   Oritavancin (n = 204)   Vancomycin (n = 201)   % Difference (95% CI)
Early clinical evaluation (ECE)   FDA primary endpoint: Cessation of spread, absence of fever, no rescue antibiotics   166 (81.4%)   162 (80.6%)   0.8 (-6.9, 8.4)
≥20% reduction of lesion area   190 (93.1%)   175 (87.1%)   6.1 (0.5, 11.6)*
Post therapy evaluation (PTE)   EMA primary endpoint: Investigator-assessed clinical cure   170 (83.3%)   169 (84.1%)   -0.7 (-7.9, 6.4)

*p value=0.032

When the SOLO I and SOLO II studies are combined, the safety profiles were similar across treatment groups (safety population: 976 in oritavancin, 983 in vancomycin). Overall, 55.3% of patients on oritavancin and 56.9% of patients on vancomycin were reported to experience at least one adverse event. Fewer treatment emergent adverse events considered by investigators as related to study drug were reported among patients treated with oritavancin than vancomycin (22.2% vs. 28.4% p=0.002). Proportions of patients with adverse events leading to study drug discontinuation were low and comparable between oritavancin and vancomycin (3.7% and 4.2%, respectively).

The design of the Phase 3 SOLO clinical trial program was agreed to through the SPA process with the FDA and was also reviewed formally by the EMA. The pivotal Phase 3 trials are designed to support the filing of a New Drug Application in the United States as well as a Marketing Authorization Application in Europe.

About The Medicines Company The Medicines Company ( NASDAQ : MDCO ) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well being of critically ill patients. The Medicines Company's website is www.themedicinescompany.com .

Conference call There will be a conference call with management today at 9:00 a.m. Eastern Time to discuss SOLO trial results and outlook. This call is being webcast and can be accessed via The Medicines Company website at www.themedicinescompany.com .

The dial in information is listed below: Domestic Dial In: 866 318.8614 International Dial In: +617 399.5133 Passcode for both dial in numbers: 17469621

Replay is available from 11:00 a.m. Eastern Time following the conference call through July 16, 2013. To hear a replay of the call dial 888 286.8010 (domestic) and +617 801.6888 (international). Passcode for both dial in numbers is 21739780.

Forward-looking Statements Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on May 9, 2013, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

Contact: Michael Mitchell The Medicines Company 973-290-6097 michael.mitchell@themedco.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 101

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 49

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 91

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 177

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 121

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 95

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 108

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 60

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Work Protective Gear to Enhance Safety and Comfort

Updated Category News Views 209

Revolutionizing Workplace Safety with New Gear Workplace injuries remain a significant concern across various job sites, with issues such as severe cuts and long-lasting knee damage becoming all too common. These challenges not only compromise the well-being of workers but also inflate costs for employers. Many workers often overlook critical personal protective equipment...

Continue Reading
Exploring Innovations in Toxicology at Upcoming ACMT Meeting

Updated Category News Views 380

Innovative Toxicology Research Unveiled at the 2025 ACMT Meeting In an exciting announcement, the American College of Medical Toxicology (ACMT) is gearing up for its 2025 Annual Scientific Meeting and Symposia, set to take place from April 2 to 6 at the Fairmont Hotel in Vancouver. This year promises an inspiring lineup featuring five days filled with groundbreaking...

Continue Reading
ConnectM Technology Solutions' Live Investor Webinar Invitation

Updated Category News Views 77

ConnectM Announces Exclusive Investor Webinar ConnectM Technology Solutions, Inc. (NASDAQ: CNTM), a pioneering technology firm in the electrification economy, is hosting a special investor webinar on March 4, at 4:15 p.m. Eastern Time. This event is a unique opportunity to learn about the company's strategies and insights in a rapidly evolving industry. Discover the...

Continue Reading
Deadline for SelectQuote Investors Approaching Soon

Updated Category News Views 177

Investors Urged to Take Action on SelectQuote Losses Attention investors! If you have experienced financial losses in SelectQuote, now is the time to act. Faruqi & Faruqi, LLP is leading the charge in investigating claims on behalf of investors who may have suffered due to the company's recent developments. Investors are proudly encouraged to reach out if they believe...

Continue Reading
Empowering Girls in Sports: NRPA and Nike's Initiative

Updated Category News Views 486

NRPA and Nike Unite for Gender Equity in Youth Sports The National Recreation and Park Association (NRPA) has joined forces with Nike, highlighting a shared commitment to advancing gender equity in youth sports. This partnership emphasizes the necessity of equitable access to sporting opportunities for all youth, especially girls, to ensure they thrive in their...

Continue Reading